

## CANCER

## Development of a stress response therapy targeting aggressive prostate cancer

Hao G. Nguyen,<sup>1\*</sup> Crystal S. Conn,<sup>1\*†</sup> Yae Kye,<sup>1</sup> Lingru Xue,<sup>1</sup> Craig M. Forester,<sup>2</sup> Janet E. Cowan,<sup>1</sup> Andrew C. Hsieh,<sup>1‡</sup> John T. Cunningham,<sup>1§</sup> Charles Truillet,<sup>3</sup> Feven Tameire,<sup>4</sup> Michael J. Evans,<sup>3</sup> Christopher P. Evans,<sup>5</sup> Joy C. Yang,<sup>5</sup> Byron Hann,<sup>6</sup> Constantinos Koumenis,<sup>4</sup> Peter Walter,<sup>7</sup> Peter R. Carroll,<sup>1</sup> Davide Ruggero<sup>1,8†</sup>

Copyright © 2018  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim  
to original U.S.  
Government Works

Oncogenic lesions up-regulate bioenergetically demanding cellular processes, such as protein synthesis, to drive cancer cell growth and continued proliferation. However, the hijacking of these key processes by oncogenic pathways imposes onerous cell stress that must be mitigated by adaptive responses for cell survival. The mechanism by which these adaptive responses are established, their functional consequences for tumor development, and their implications for therapeutic interventions remain largely unknown. Using murine and humanized models of prostate cancer (PCa), we show that one of the three branches of the unfolded protein response is selectively activated in advanced PCa. This adaptive response activates the phosphorylation of the eukaryotic initiation factor 2- $\alpha$  (P-eIF2 $\alpha$ ) to reset global protein synthesis to a level that fosters aggressive tumor development and is a marker of poor patient survival upon the acquisition of multiple oncogenic lesions. Using patient-derived xenograft models and an inhibitor of P-eIF2 $\alpha$  activity, ISRIB, our data show that targeting this adaptive brake for protein synthesis selectively triggers cytotoxicity against aggressive metastatic PCa, a disease for which presently there is no cure.

## INTRODUCTION

Adaptation to cellular stress, driven by oncogenic lesions, is one of the most fundamental and poorly understood features of cancer cells (1, 2). Multiple oncogenes sustain uncontrolled cancer cell growth and division by stimulating the production of molecular “building blocks,” such as proteins and outputs of anabolic metabolism. However, this poses an onerous expenditure of cellular resources, and it remains poorly understood how cancer cells adapt to this increased metabolic load. One example is an increase in total proteins being synthesized, because cancer cells need to sustain augmented growth and division. For instance, more than 65% of the energy in the cell is devoted to the bioenergetically expensive process of protein synthesis that is greatly increased in most cancers (3). Left unchecked, infinite increases in the cancer cell’s biosynthetic demand would tilt the balance from continuous growth and division to cell death. Therefore, increases of biosynthetic processes place a high demand on cancer cells and are a source of constant stress that must be carefully regulated by the activation of appropriate checkpoints, which remain poorly

understood. How then do cancer cells accommodate overwhelming stress such as an increased protein burden? Are cytoprotective responses activated in aggressive disease, and do they represent a point of vulnerability that can be exploited for cancer therapy?

Increased protein synthesis and the flux in the endoplasmic reticulum (ER) create a state of proteotoxic stress associated with the accumulation of misfolded proteins (4–6). This ER stress activates the unfolded protein response (UPR). The UPR is composed of three signaling arms: ATF6 (activating transcription factor 6) with transcriptional activity to promote ER homeostasis, IRE1 (inositol-requiring enzyme 1) to control splicing of the transcription factor XBP1 enhancing ER gene expression, and PERK [PKR (RNA-activated protein kinase)-like ER-associated protein kinase], which promotes downstream phosphorylation of eIF2 $\alpha$  (eukaryotic initiation factor 2- $\alpha$ ) (P-eIF2 $\alpha$ ) on serine 51 (4). Unlike the other arms of the UPR, PERK P-eIF2 $\alpha$  creates a direct “brake” for general protein synthesis because of the conversion of eIF2 from a substrate of the ternary complex, which is necessary to promote the initiation step of mRNA translation, to an inhibitor of this complex (7, 8). Although UPR activation has been associated with cancer, it remains poorly understood which oncogenes and/or combinations of oncogenes control distinct arms of this pathway in vivo during the initiation or progression of tumor development. It is also unclear whether and when the UPR is activated during the course of cancer evolution, its specific requirements in distinct phases of tumorigenesis, and the potential druggability of this stress adaptation pathway in human cancers.

Here, we set out to address these outstanding questions by investigating cancer development within a specialized secretory epithelial tissue. The prostate is a walnut-sized conglomerate of tubular or saclike glands, dedicated to the production of proteinaceous secretory fluid. One of the early consequences of human primary prostate cancer (PCa) is a major remodeling of the cancer cell proteome associated with increases in protein biosynthesis (9–11). For example, loss of the PTEN (phosphatase and tensin homolog) tumor

<sup>1</sup>School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA. <sup>2</sup>Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation, UCSF, San Francisco, CA 94158, USA. <sup>3</sup>Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA 94158, USA. <sup>4</sup>Department of Radiation Oncology, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. <sup>5</sup>Department of Urology, University of California Davis School of Medicine, Sacramento, CA 95817, USA. <sup>6</sup>Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA 94158, USA. <sup>7</sup>Department of Biochemistry and Biophysics, UCSF, Howard Hughes Medical Institute, San Francisco, CA 94158, USA. <sup>8</sup>Department of Cellular and Molecular Pharmacology, UCSF, San Francisco, CA 94158, USA.

\*These authors contributed equally to this work.

†Corresponding author. Email: crystal.conn@ucsf.edu (C.S.C.); davide.ruggero@ucsf.edu (D.R.)

‡Present address: Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA 98195, USA.

§Present address: Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.


suppressor and hyperactivation of the oncogene MYC, accounting for nearly 50% of the lethal metastatic form of human PCa (12, 13), have major effects on protein synthesis (14–17). Thus, we reasoned that the prostate would provide a good model to understand the mechanisms by which oncogenic cells buffer the burden of increased protein synthesis to prevent proteotoxic stress during cancer formation.

## RESULTS

### MYC amplification with PTEN loss diminish oncogenic increases of global protein synthesis in lethal murine PCa

We modeled distinct stages of human PCa in the mouse, using a newly generated conditional transgenic MYC mouse, where the overexpression of *C-MYC* is driven in a Cre-specific manner (*Myc<sup>Tg</sup>*), in combination with the conditional loss of *PTEN* in the prostate epithelium (*Pb-cre4;Pten<sup>fl/fl</sup>*, herein referred to as *Pten<sup>fl/fl</sup>*) (fig. S1) (18). The advantage of this mouse is that cells overexpressing *Myc<sup>Tg</sup>* can be traced through expression of green fluorescent protein (GFP) present in the targeting locus, allowing for visualization of the earliest events in tumorigenesis (fig. S1, A and B). In agreement with the notion that MYC hyperactivation may be a secondary event for human PCa development (19), we find that MYC overexpression alone in prostate epithelium (*Pb-cre4;Myc<sup>Tg</sup>*, herein referred to as *Myc<sup>Tg</sup>*) increased proliferation but did not result in adenocarcinoma by 1 year of age (fig. S1, C to E). This is consistent with previous reports, which showed MYC expression under the control of similar promoters to those used here (20, 21). *Myc<sup>Tg</sup>* mice with concomitant loss of PTEN in prostate tissue (*Pten<sup>fl/fl</sup>;Myc<sup>Tg</sup>*) showed significant enlargement of prostate growth by 6 weeks of age ( $P < 0.0003$ ) and accelerated development of high-grade prostatic intraepithelial neoplasia (HgpIN) compared to mice with loss of PTEN alone (Fig. 1, A and B). PTEN loss and MYC amplification cooperated to develop adenocarcinoma by 10 weeks (Fig. 1B), resulting in marked increases in *Pten<sup>fl/fl</sup>;Myc<sup>Tg</sup>* tumor size visualized by ultrasound (Fig. 1C). This aggressive oncogenic progression significantly decreased overall survival ( $P < 0.05$ ), with a mean life span of 75 weeks (Fig. 1D). Collectively, this genetically engineered mouse model (GEMM) recapitulates aggressive human PCa and results in decreased survival.

To evaluate the effects of these key oncogenes on global protein synthesis, we assessed newly synthesized proteins by incorporation of  $^{35}\text{S}$ -labeled methionine in organoid cultures. We established pri-



**Fig. 1. *Myc<sup>Tg</sup>* and loss of PTEN cooperate for aggressive PCa development, resulting in decreased survival.** (A) Total dehydrated prostate weights from 6- and 10-week-old mice were averaged for each genotype ( $n = 3$  to 6 mice per arm, mean  $\pm$  SEM). wild-type, WT. (B) Phenotypic penetrance percentages for low-grade prostatic intraepithelial neoplasia (LgPIN), HgpIN, and cancer in anterior prostate tissues from 6- and 10-week-old mice evaluated by hematoxylin and eosin (H&E) staining. (C) Left: Representative ultrasound images of prostate tumors at 7 months outlined in yellow from indicated genotypes; scale bars, 9 mm. Right: Quantification of prostate tumor size in mice with an average age of 8 months ( $n = 5$  mice per arm, mean  $\pm$  SEM). (D) Kaplan-Meier survival curves for mice with the indicated genotypes. Dotted line highlights the median life span of 75 weeks for *Pten<sup>fl/fl</sup>;Myc<sup>Tg</sup>* mice. (E) Top: Representative bright-field images of three-dimensional organoid structures 6 days after seeding; scale bars, 50  $\mu\text{m}$ . Bottom: Western blot analyzing the organoids, showing P-AKT, PTEN, GFP for *Myc<sup>Tg</sup>*, and  $\beta$ -actin. (F) Newly synthesized proteins measured by  $^{35}\text{S}$  methionine/cysteine incorporation in organoids (left panel), with quantification relative to WT littermates (right panel) ( $n = 5$ , mean  $\pm$  SEM). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , *t* test.

mary mouse three-dimensional organoid cultures to recapitulate the cellular environment of the murine prostate gland ex vivo (Fig. 1E) (22). Organoids were derived from dissociated mouse prostate tissue containing a mixed population of luminal and basal cell types to mimic the histology observed in vivo (23). Western blot analysis confirmed that *Myc<sup>Tg</sup>* expression and PTEN loss were evident and associated with increased GFP expression and AKT phosphorylation (Fig. 1E). Consistent with the known ability of these major oncogenic pathways to increase protein synthesis (24, 25), either loss of PTEN or MYC hyperactivation significantly increased global protein synthesis by about 20% ( $P < 0.0003$  for both). On the contrary, we observed

an unanticipated but significant dampening in global protein synthesis in  $Pten^{fl/fl};Myc^{Tg}$  mice ( $P = 0.01$ ), despite the fact that these mice developed more aggressive PCa (Fig. 1F). This observation revealed an interesting paradox. It suggested that despite the presence of two oncogenic lesions that individually up-regulate protein synthesis, a yet unknown adaptive response may take place when protein synthesis is up-regulated beyond a specific threshold in aggressive PCa.

### Aggressive PCa activates a key cellular stress response during tumor development


Proteins that are synthesized in the secretory pathway amount to about 30% of the total proteome in most eukaryotic cells (4, 6). Although UPR activation can be studied with pharmacological inducers of ER stress, under physiological processes, the activation of the UPR may reduce the unfolded protein load through several prosurvival mechanisms, including the expansion of the ER membrane and the selective synthesis of key components of the protein folding and quality control machinery (26). To address how cancer cells respond and adapt to a protein synthesis burden *in vivo* and downstream of specific oncogenic lesions, we tested whether a specific molecular signature of the UPR may be activated in  $Pten^{fl/fl}$ - versus  $Pten^{fl/fl};Myc^{Tg}$ -derived PCa.

We performed quantitative immunofluorescence (IF) staining for cleaved ATF6, P-IRE1, and P-PERK during tumor development to test whether the UPR was activated during PCa progression. Visualizing UPR expression within prostatic tissue at 10 weeks of age allowed us to directly gauge the activity of each arm during neoplasia. Whereas the ATF6 and IRE1 branches of the UPR were relatively equally activated in  $Pten^{fl/fl}$  and  $Pten^{fl/fl};Myc^{Tg}$  tissue (fig. S2A), PERK phosphorylation was selectively increased by over 15-fold within  $Pten^{fl/fl};Myc^{Tg}$  tissue compared to its near absence in  $Pten^{fl/fl}$  cells (Fig. 2A). Thus, PERK activation is a distinct response that may promote tumorigenesis in aggressive PCa driven by the cooperation of two oncogenic lesions. To confirm the selective activation of PERK signaling in  $Pten^{fl/fl};Myc^{Tg}$  mice, we evaluated the downstream signaling to eIF2 $\alpha$ . P-eIF2 $\alpha$  was also markedly increased in  $Pten^{fl/fl};Myc^{Tg}$  mice and strongest within areas of PIN but remained absent within  $Pten^{fl/fl}$  tissues (Fig. 2, A and B, and fig. S2B). The expression of the ER-specific molecular chaperone BiP was not changed and was also high in normal prostatic tissues in agreement with the secretory role of these glands (fig. S2C). Collectively, this analysis reveals two independent, yet linked mechanisms: (i) activation of each UPR pathway in PCa *in vivo* and (ii) activation of a P-eIF2 $\alpha$ -dependent response selectively


in  $Pten^{fl/fl};Myc^{Tg}$  mice, which display more aggressive PCa progression and reduced survival.

### Rebalancing protein synthesis through P-eIF2 $\alpha$ is required for aggressive PCa progression

A general UPR response may promote adaptation to proteotoxic and ER stress, whereas the activation of P-eIF2 $\alpha$  could place a direct brake on the overwhelming burden of protein synthesis that occurs during more aggressive tumorigenesis. To test this hypothesis, we used our organoid cultures, which recapitulate the *in vivo* phenotype. The  $Pten^{fl/fl};Myc^{Tg}$  cultures show increased activation of P-PERK, P-eIF2 $\alpha$ , and expression of ATF4, which is a known target of the PERK–P-eIF2 $\alpha$  axis (Fig. 3A). To determine whether the activation of this adaptive response was altering global protein synthesis, we used a small-molecule inhibitor of P-eIF2 $\alpha$  activity, ISRIB, a compound that selectively reverses the effects of eIF2 $\alpha$  phosphorylation (fig. S3A) (27, 28). Specifically, P-eIF2 $\alpha$  binds its dedicated guanine nucleotide exchanging factor (GEF), eIF2B, with enhanced affinity relative to eIF2 $\alpha$ . Thus, P-eIF2 $\alpha$  sequesters eIF2B from interacting with eIF2 $\alpha$  to exchange guanosine diphosphate with guanosine triphosphate, which is an essential step to form the translation preinitiation complex. ISRIB increases eIF2B GEF activity by stabilizing it into a



**Fig. 2. The cooperation of MYC and loss of PTEN selectively activates the adaptive PERK–P-eIF2 $\alpha$  arm of the UPR.** (A) Left: Representative IF images of P-PERK/cytokeratin 5 (CK5) or P-eIF2 $\alpha$ /CK5 co-staining with DAPI (4',6-diamidino-2-phenylindole) used to visualize the nuclei within anterior prostate tissue from 10-week-old mice; scale bars, 100  $\mu$ m. P-PERK or P-eIF2 $\alpha$  expression quantified relative to DAPI ( $n = 3$  mice per arm, with four images averaged per mouse, mean  $\pm$  SEM). (B) Representative IF images of P-eIF2 $\alpha$ /CK5 co-staining with DAPI in anterior prostate tissue from 6-week-old mice (scale bars, 100  $\mu$ m) (left panel) and directly within areas of PIN (right panel). Lower panel depicts a model showing the timeline of PCa development within  $Pten^{fl/fl};Myc^{Tg}$  mice, highlighting when P-eIF2 $\alpha$  is expressed.  $**P < 0.01$ ,  $t$  test.



**Fig. 3. Inhibition of P-eIF2 $\alpha$  activity rebalances protein synthesis and prevents PCa progression.** (A) Representative Western blot highlighting PERK signaling in organoid cultures. (B) Left: Total newly synthesized proteins measured by  $^{35}\text{S}$  methionine/cysteine incorporation and Western blot showing P-eIF2 $\alpha$  and ATF4 in organoids treated with dimethyl sulfoxide (DMSO) or ISRIB (500 nM) for 6 hours. Right: Quantification of radioactive pulse relative to loading, depicted as percent over WT ( $n = 3$ , mean  $\pm$  SEM). (C) Schematic of preclinical trial for escalating dosage and MRI schedule over 6 weeks. (D) Representative scans of two ISRIB-treated mice after 1 and 6 weeks of treatment for comparison. Tumor is outlined in red, and arrows highlight the seminal vesicles (SV) surrounding the tumor. (E) Quantification of tumor size as fold change relative to baseline volume at 3- and 6-week time points (mean  $\pm$  SEM). \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , t test.

decamer holoenzyme to enhance the binding of the eIF2 factor, thereby restoring protein synthesis regardless of eIF2 $\alpha$  phosphorylation (29). In Pten $^{\text{fl/fl}}$  organoid cultures, protein synthesis was not altered by ISRIB treatment, despite the drug inhibiting P-eIF2 $\alpha$  activity, as confirmed by a decrease in ATF4 expression (Fig. 3B). Conversely, we observed a marked increase of newly synthesized proteins in Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  cells, which show increased P-eIF2 $\alpha$  signaling (Fig. 3B). Together, these experiments indicate that P-eIF2 $\alpha$  creates an adaptive response to relieve the burden of increased protein synthesis within Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  oncogenic cells.

In addition to PERK, other kinases can phosphorylate the eIF2 $\alpha$  subunit upon distinct stress signals: GCN2 (amino acid deprivation), PKR (viral infection), and HRI (heme deprivation) (30). To assess whether the selective adaptive response observed during aggressive PCa development of Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  mice was specific to the PERK–P-eIF2 $\alpha$  axis, we undertook a genetic approach, using Perk $^{\text{fl/fl}}$  mice to evaluate the loss of PERK in the prostate gland (fig. S3B) (31). Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$ ;Perk $^{\text{fl/fl}}$  mice showed markedly reduced prostate growth compared to Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  mice, with weights similar to Pten $^{\text{fl/fl}}$  and Pten $^{\text{fl/fl}}$ ;Perk $^{\text{fl/fl}}$  mice at 10 weeks

of age (fig. S3C). The reduction in prostate size corresponded to a decrease in cancer progression and in cell proliferation (fig. S3, D and E). To determine the consequence of PERK loss for P-eIF2 $\alpha$  signaling in PCa development, we monitored P-eIF2 $\alpha$  expression by IF staining. The activation of P-eIF2 $\alpha$  was reduced by 70% in Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$ ;Perk $^{\text{fl/fl}}$  tissue compared to Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  (fig. S3F). These data strongly suggest that the P-eIF2 $\alpha$ -dependent adaptive stress response is driven to a large extent by PERK signaling.


Our studies demonstrated that P-eIF2 $\alpha$  is directly activated in the early stage of Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  tumorigenesis, being visible in benign tissue and increasing in HgPIN, which may reflect a distinct point of vulnerability for aggressive PCa (Fig. 2). To evaluate the necessity of P-eIF2 $\alpha$  for promoting tumor growth or maintenance in vivo, we conducted a preclinical trial. Mice with developed tumors were imaged by magnetic resonance imaging (MRI) to confirm a measurable baseline of prostate volume per mouse and then grouped into cohorts for either vehicle or ISRIB treatment daily over the course of 6 weeks (Fig. 3C). Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  mice showed tumor regression within 3 weeks of ISRIB treatment, with no signs of toxicity, whereas all Pten $^{\text{fl/fl}}$  mice showed continued tumor growth (Fig. 3, D and E, fig. S4A, and table S1). By 6 weeks, Pten $^{\text{fl/fl}}$

mice showed an approximate 40% increase in growth over individual baseline measurements, whereas ISRIB-treated Pten $^{\text{fl/fl}}$ ;Myc $^{\text{Tg}}$  mice demonstrated no progression in tumor size. In addition, we evaluated the immune cell infiltration, marked by the pan-leukocyte antibody CD45 after 3 weeks of ISRIB treatment and observed no significant changes regardless of prostate tumor genotype and treatment (fig. S4B). Further analysis of immune cell populations did not demonstrate substantial differences in total T cell or myeloid populations, including dendritic cells, macrophages, and neutrophils (fig. S4, C and D). Of the intertumoral immune cells examined, less than 5% were either CD4 $^+$  or CD8 $^+$  T cells, as expected for the Pten $^{\text{fl/fl}}$  murine prostate model (32). Although we cannot exclude the possibility that ISRIB may be remodeling tumor immunity during initial treatment, this was not evident after 3 weeks of treatment. Together, these studies reveal that P-eIF2 $\alpha$  signaling is functionally relevant in aggressive PCa and that this adaptive response is therapeutically targetable in vivo using the small-molecule inhibitor ISRIB.

To extend our observations directly to human disease, we created human cell lines to mimic our genetic mouse models. Human RWPE-1

epithelial cells were created to stably knock down PTEN (shPTEN) with or without MYC overexpression (MYC<sup>OE</sup>, Fig. 4A). The combination of PTEN loss with increased MYC expression activated PERK signaling and P-eIF2 $\alpha$ , showing that the adaptive response that we

had observed in mice is also triggered in human prostate cells. To understand the requirement for this stress response checkpoint in human cells, we treated each cell line with ISRIB and observed a marked increase in apoptosis, independent of alterations in proliferation, specifically in shPTEN;MYC<sup>OE</sup> cells relative to control samples (Fig. 4B and fig. S5A).



**Fig. 4. High P-eIF2 $\alpha$  expression in human prostate tumors with loss of PTEN function is associated with increased risk of metastasis or death after surgery.** (A) Representative Western blot showing PTEN, MYC, P-PERK, P-eIF2 $\alpha$ , and total eIF2 $\alpha$  expression with  $\beta$ -actin loading control (Ctrl) in human prostatic RWPE-1 cell lines. (B) Quantification of annexin V-positive cells analyzed by flow cytometry relative to control cells after treatment with DMSO or 500 nM ISRIB for 9 hours ( $n = 3$ , mean  $\pm$  SEM) \* $P < 0.05$ ,  $t$  test. (C) Kaplan-Meier analysis of clinical progression-free survival [progression defined as visceral or bone metastasis or PCSM] for patients with normal PTEN expression versus PTEN loss and relative MYC expression identified by IF from the TMA. (D) Kaplan-Meier analysis of MET/PCSM for patients with normal PTEN expression versus PTEN loss grouped by eIF2 $\alpha$  phosphorylation. (E) Cox proportional hazards regression results are shown in a Forest plot of hazard ratios and 95% CI for factors associated with risk of clinical progression after surgery. Independent factors are tumor with PTEN loss/low P-eIF2 $\alpha$  or PTEN loss/high P-eIF2 $\alpha$  versus a reference group with normal PTEN expression; age in years; PSA in nanograms per milliliter; Gleason score  $> 7$  versus 6; and pathological stage T3-T4 versus T2 at the time of prostatectomy.

**High P-eIF2 $\alpha$  expression with loss of PTEN is associated with an increased risk of metastasis after surgery**

To further examine the clinical relevance of high P-eIF2 $\alpha$  downstream of PTEN loss, we built a human tissue microarray (TMA) consisting of 424 tumors and analyzed the expression of PTEN, c-MYC, and P-eIF2 $\alpha$ . On the basis of our GEMMs, we predicted that the combination of PTEN loss and P-eIF2 $\alpha$  would associate with advanced PCa. We selected an array of patients with PCa ranging from low to high risk, who received surgery as a curative treatment with a median of 10 years of follow-up to accurately evaluate the incidence of clinical progression, a composite outcome representing visceral or bone metastasis or PCa-specific mortality (MET/PCSM) (Table 1). We used quantitative IF of P-eIF2 $\alpha$ , c-MYC, and PTEN normalized to adjacent benign tissue (fig. S6, A and B) and then evaluated associated risk for MET/PCSM. After controlling for age, prostate-specific antigen (PSA), Gleason score, and pathological staging, the analysis showed that patients with PTEN loss/high MYC expression were more likely to experience metastatic progression than patients with PTEN loss or high MYC alone (Fig. 4C).

Our data from the GEMMs and human prostatic cell lines suggested that P-eIF2 $\alpha$  is a targetable adaptive response downstream of PTEN loss and MYC hyperactivation. Hence, we next examined the associated risk of progression in patients with PTEN loss and high P-eIF2 $\alpha$  at the time of surgery. The rate of MET/PCSM-free survival was significantly lower in patients with high P-eIF2 $\alpha$  and PTEN loss compared to PTEN loss alone ( $P < 0.01$ ) (Fig. 4D). Only 4% of patients with PTEN loss and low P-eIF2 $\alpha$  succumbed to metastasis or death, whereas 19% of patients with PTEN loss and high P-eIF2 $\alpha$  showed MET/PCSM by 10 years after surgical intervention with the intention to cure the disease. Furthermore, patients with high P-eIF2 $\alpha$  and PTEN loss had a higher risk

of MET/PCSM compared to patients with no PTEN loss, with a hazard ratio of 5.40 [95% confidence interval (CI), 2.46 to 11.86;  $P < 0.01$ ], whereas other variables that may affect the risk were not significantly different (Fig. 4E). MYC overexpression with either low or high P-eIF2 $\alpha$  did not associate with increased risk of MET/PCSM (fig. S6C), supporting our findings that MYC alone does not drive PCa. Notably, high P-eIF2 $\alpha$  expression played a role equivalent to the MYC oncogene in combination with loss of PTEN at predicting metastatic progression (Fig. 4, C and D), yet unlike MYC, P-eIF2 $\alpha$  may be a druggable target. Together, the combination of P-eIF2 $\alpha$  and PTEN loss may serve as

a predictor for cancer progression after curative treatment, which is independent of the traditional risk assessment system using PSA, cancer grade, and cancer stage.

We next evaluated the discriminatory properties of high P-eIF2 $\alpha$  and PTEN loss as a prognostic marker independent from the most commonly used risk assessment score in the clinic, CAPRA-S (Cancer of the Prostate Risk Assessment after Surgery) (33). We used the *c*-index (concordance index) to evaluate the ability of the protein signature of high P-eIF2 $\alpha$  with loss of PTEN to discriminate between individual patients who did or did not succumb to metastasis or death after surgery. Currently, clinicians depend on genomic risk to individualize treatment decisions using three available gene expression tests: Prolaris, Decipher, and OncotypeDx (34). The Prolaris test relies on the average expression of 31 cell cycle progression (CCP) genes and was validated using the same cohort of patients used in the TMA (35). Within the same patients, the Prolaris-CCP panel has a combined *c*-index of 0.77 (CAPRA-S + CCP) (35), whereas high P-eIF2 $\alpha$  and PTEN loss has a *c*-index of 0.80 (fig. S6D). These findings show that concurrent high P-eIF2 $\alpha$  and PTEN loss serves as an independent predictor with improved prognostic accuracy over standard clinicopathologic testing for discriminating which individuals may experience metastatic progression.

### P-eIF2 $\alpha$ is a targetable adaptive response in aggressive human PCa

We next sought to functionally evaluate whether we could target the UPR pathway, specifically through P-eIF2 $\alpha$ , in advanced human PCa. Although it is historically difficult to generate human prostate patient-derived xenograft (PDX) models (36), we were successful in generating models with similar characteristics to the Pten<sup>fl/fl</sup>;Myc<sup>Tg</sup> mice to assess the effects of ISRIB on cancer growth and mortality. In particular, we generated two PDX models: one derived from a primary tumor, herein referred to as pPCa, and one derived from a lymph node metastasis in the left internal iliac chain from the same patient, herein referred to as mPCa (Fig. 5A). The pPCa-PDX tumor had significantly lower MYC expression than the mPCa-PDX tumor ( $P < 0.01$ ), but both showed loss of PTEN with increased P-AKT expression (Fig. 5B and fig. S7A). We also observed a significant increase in P-eIF2 $\alpha$  only in the mPCa ( $P < 0.01$ ; Fig. 5B).

To test the therapeutic efficacy of ISRIB in human PCa, we performed a preclinical trial on the stably passaged PDX model. Targeting P-eIF2 $\alpha$  pharmacologically significantly prolonged survival in mice bearing the metastatic tumor with high P-eIF2 $\alpha$  ( $P < 0.01$ ; Fig. 5C), whereas the effectiveness of ISRIB treatment was short-lived in pPCa tumor. Consistent with our GEM model, the mPCa-PDX model, with high expression of P-eIF2 $\alpha$ , displayed significant tumor regression and cell death ( $P < 0.01$ ), as demonstrated by increased terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining and cleaved caspase 3 expression after only 9 days of ISRIB treatment (Fig. 5, D and E, and fig. S7B). Conversely, the pPCa-PDX model, with low P-eIF2 $\alpha$ , did not show regression but stabilized with eventual tumor regrowth and no significant cell death (Fig. 5, D and E, and fig. S7B). These findings demonstrate that attenuating P-eIF2 $\alpha$  activity with ISRIB elicits a potent antitumor effect in a humanized model of advanced PCa.


We next determined whether a metastatic PCa tumor, harboring high MYC and loss of PTEN activity in a complex genetic background of human PCa, relies on eIF2 $\alpha$  phosphorylation as an adaptive response to restrain global protein synthesis. Therefore, we assessed

**Table 1. Characteristics of patients included in the TMA.** Baseline characteristics of the TMA cohort consisting of 424 tumor samples, where 58 years is the average age at diagnosis. More than 50% of the cohort had pathological Gleason grade 7 or higher, and 75% had organ-confined disease (pathological stage T2). Median follow-up was 10 years.

Patient characteristics of TMA	Value	n	(%)
<b>Race/ethnicity</b>	Native American	1	0
	Asian/Pacific Islander	13	3
	African-American	14	3
	Caucasian	359	85
	Mixed	25	6
	Unknown	12	3
<b>Biopsy Gleason grade</b>	3 + 3	263	64
	3 + 4	95	23
	4 + 3	25	6
	8 – 10	29	7
	Missing	12	—
<b>Clinical T stage</b>	T2	296	98
	T3	5	2
	T4	2	1
	Missing	121	—
<b>Pathologic Gleason grade</b>	3 + 3	184	43
	3 + 4	173	41
	4 + 3	45	11
	8 – 10	22	5
<b>Pathologic T stage</b>	T2	313	75
	T3	102	24
	T4	5	1
	Missing	4	—
<b>Pathologic N stage</b>	NX	200	48
	N0	208	50
	N1	7	2
	Missing	9	—
<b>Surgical margins</b>	No	354	83
	Yes	70	17
<b>Adverse path (Gleason Grade <math>\geq</math> 4 + 3 or pT3a/pN1)</b>	No	291	69
	Yes	133	31

newly synthesized proteins in vivo by measuring the incorporation of *O*-propargyl-puromycin (OP-Puro) within the primary and metastatic tumor-derived PDXs, which have low or high P-eIF2 $\alpha$ , respectively. Upon ISRIB treatment, we observed a marked increase in global protein synthesis specifically in the mPCa PDX, but no change

in pPCa tumors where P-eIF2 $\alpha$  expression was not up-regulated (Fig. 5F). To further assess the functional relevance of P-eIF2 $\alpha$  signaling, we decreased ATF4 expression in vivo using intratumor knock-down by small interfering RNA (siRNA). Within the area of intratumor ATF4 loss, we observed apoptosis and decreased proliferation




**Fig. 5. Inhibition of P-eIF2 $\alpha$  axis results in tumor regression and prolongs survival in a humanized model of metastatic PCa.** (A) Schematic highlighting origin of PDX tumors from primary (pPCa) or lymph node metastasis (mPCa). Tumors from selected patients with high-risk features, based on Gleason score and clinical stage or with lymph node metastases determined by  $^{68}\text{Ga}$ -PSMA-11 positron emission tomography (PET) scans, were used to generate PDXs. Primary and metastatic tumors were confirmed from tissue collected at the time of surgery and immediately implanted into immunodeficient NOD scid gamma (NSG) mice. (B) Representative IF images of MYC/CK8 (epithelial cell marker), P-AKT/CK8, or P-eIF2 $\alpha$ /CK8, co-staining with DAPI from benign (Ben) tissue adjacent to pPCa or mPCa tumors; scale bars, 50  $\mu\text{m}$ . Right: Quantification of protein expression as relative mean IF intensity normalized to adjacent stromal tissue. (C) Kaplan-Meier tumor survival curves for mice bearing pPCa or mPCa tumors treated with ISRIB (10 mg/kg) or vehicle ( $n = 8$ , per cohort;  $^{**}P = 0.01$ , log-rank test). The survival curves represent mice euthanized when tumors reached an end point of 2 cm or when the mice showed clear signs of morbidity. (D) Representative tumor sizes after 10 days of treatment. (E) Representative TUNEL staining and quantification of PDX tumors treated with vehicle or ISRIB (10 mg/kg); scale bars, 100  $\mu\text{m}$  ( $n = 3$ ,  $^{***}P < 0.001$ ,  $t$  test). (F) Quantification of newly synthesized proteins in vivo, assessed by incorporation of OP-Puro within PDX treated with ISRIB (10 mg/kg) or vehicle ( $n = 3$  to 4 per arm, mean  $\pm$  SEM;  $^{*}P < 0.05$ ,  $t$  test). n.s., not significant. MFI, mean fluorescence intensity.

assessed by TUNEL and Ki67 staining of mPCa PDX (fig. S7C). This demonstrated that inhibition of the PERK-eIF2 $\alpha$  axis by a genetic or pharmacological approach effectively results in cell death of aggressive PCa in vivo.

### Targeting P-eIF2 $\alpha$ activity reduced metastasis and prolonged survival in a PDX model of metastatic castration-resistant PCa

In hormone-sensitive metastatic PCa, androgen deprivation therapy (ADT) remains the mainstay treatment; however, these tumors inevitably develop resistance to ADT and progress into the lethal form of metastatic castration-resistant PCa (mCRPC) (37). Characterization of the hormone-sensitive metastatic disease has not been predictive of outcomes in the clinical setting of lethal mCRPC (38, 39). To directly study the contribution of P-eIF2 $\alpha$  to metastasis, we generated an additional PDX (herein mCRPC PDX) derived from a patient with mCRPC despite prolonged treatment with complete androgen blockage using leuprolide (ADT) and antiandrogen therapy (enzalutamide) (37). Three weeks after implantation of the mCRPC tumor under the mouse renal capsule, we observed tumor dissemination to the liver, distant kidney, lymph nodes, and spleen (fig. S8, A and B). The mCRPC PDX line continued to exhibit metastatic dissemination in the mouse host after multiple passages and retained histological and molecular characteristics of the original tumor. The distant metastatic lesions exhibited loss of PTEN, high MYC, and high P-eIF2 $\alpha$  expression (Fig. 6A and fig. S8C).

To examine the role of P-eIF2 $\alpha$  from the early stages of metastatic growth to late stages of dissemination, we used a prostate-specific membrane antigen [ $^{68}\text{Ga}$ -PSMA-11 PET/computed tomography (CT)] scan to trace the progression of very small metastases from early to late stages of dissemination, which were not visible by conventional imaging modalities such as  $^{18}\text{F}$ -DG PET/CT (fig. S8D) (40). Prostate-specific membrane antigen (PSMA) is highly expressed on the surface of PCa cells and allows sensitive staging to evaluate therapy response in the clinical setting (40). We subjected mice bearing liver or distal metastasis (confirmed by PSMA PET) to either vehicle or ISRIB treatment (Fig. 6, B and C). Inhibition of P-eIF2 $\alpha$  with ISRIB significantly prolonged survival in



**Fig. 6. ISRIB treatment decreases metastatic progression in an advanced castration-resistant PCa PDX model.** (A) Representative H&E staining and IF of P-eIF2 $\alpha$ , PTEN, and MYC expression at the primary site of implantation (mCRPC tumor), left kidney, and distant metastatic lesions in the liver; scale bars, 200  $\mu\text{m}$  (top left); 100  $\mu\text{m}$  (bottom left); and 50  $\mu\text{m}$  for IF images. (B) Schematic of preclinical trial for mCRPC tumor growth and PET/CT schedule. Representative  $^{68}\text{Ga}$ -PSMA-11 PET/CT scans on day 0 (time of treatment) and on day 7 are shown for the control versus ISRIB-treated cohorts. Uptake of the PSMA-targeted radiotracer agent is observed in the liver, lymph node, and at the site of primary tumor implantation in the left kidney capsule. Physiologic uptake of the PSMA-targeted radiotracer is also seen in the contralateral kidney and bladder because it is excreted in the urinary tract. Histologic confirmation of liver metastasis is shown by H&E staining at the time of euthanasia with dashed outlines around metastatic lesions. (C) Kaplan-Meier survival curve for mice bearing mCRPC tumors treated once per day with ISRIB (10 mg/kg) or vehicle ( $n = 3$ , per cohort); \* $P = 0.02$ , log-rank test. The survival curves represent mice euthanized when PSMA  $^{68}\text{Ga}$  PET/CT showed progression from one distant metastatic lesion to two or more sites or when the mice showed signs of becoming moribund. (D) Quantification of visible metastatic lesions on the left medial lobe of the liver at the time of euthanasia in the cohorts ( $n = 3$  per cohort); \*\*\* $P = 0.001$ .

mCRPC PDX mice bearing distal metastatic lesions ( $P = 0.01$ ; Fig. 6C). In contrast, mice with metastasis died within 10 days on vehicle treatment. By direct imaging with PSMA PET/CT, we observed substantial



metastatic regression at distal sites in mice treated with ISRIB (Fig. 6B). In addition, we confirmed a difference in metastatic progression in the liver by pathohistological analysis at time of euthanasia (Fig. 6D). Therefore, two independent PDX models of metastatic disease, one derived from a patient with early nodal metastasis (hormone-sensitive) and the second from a patient with castration-resistant PCa, demonstrated that blocking the activation of the adaptive brake on global protein synthesis via the P-eIF2 $\alpha$  axis resulted in profound tumor regression and inhibition of metastatic dissemination.

## DISCUSSION

The biological processes that allow cancer cells to balance working at capacity for tumor progression while dealing with stress phenotypes induced by the overload of cellular processes underlying rapid cell growth and division (bioenergetic processes including DNA and protein synthesis) are still poorly understood. Our data reveal a cell-autonomous mechanism wherein the activity of two major oncogenic lesions, loss of PTEN and MYC overexpression, which independently enhance protein synthesis, paradoxically, decrease global protein production when these oncogenic events coexist. This highlights the requirement for an adaptive protein homeostasis response to sustain aggressive tumor development.

Proteostasis is essential for normal cell health and viability, and as such is ensured by the coordinated control of protein synthesis, folding, and degradation (41). Although the UPR enables proteostasis to be restored during unfavorable conditions, we found that PCa cells have usurped a specific branch of this pathway for tumor growth and maintenance. The UPR consists of three main branches, yet only the PERK–P-eIF2 $\alpha$  axis is selectively triggered in this pathophysiological state to ensure continued survival of cancer cells. The mechanisms triggering the selective activation of the PERK–P-eIF2 $\alpha$  axis in PCa may be through increased protein misfolding itself, as a consequence of augmented protein synthesis at the ER, or through additional cues acting independently from the UPR (42). Nonetheless, the adaptive response involving P-eIF2 $\alpha$  signaling provides a barrier to uncontrolled increases in protein synthesis and creates a permissive environment for continued tumor growth. It is also possible that P-eIF2 $\alpha$  may affect the translation of select transcripts that are essential for aggressive oncogenesis (43–45).

It is tempting to speculate that cancer cells may have usurped mechanisms normally operating in certain cell types, whereby activation of specific branches of the UPR enables cellular differentiation or maintenance of stem cell features (46). For example, B lymphocytes normally induce the UPR during their differentiation into plasma cells to preemptively prepare for increased antibody production and secretion (47). Moreover, skeletal muscle stem cells maintain enhanced P-eIF2 $\alpha$  to promote a quiescent state required for their self-renewal capacity, which requires diminished protein synthesis (48). Such control of the UPR seen in specialized cell types may have been hijacked by specific oncogenic lesions to promote cancer survival and metastatic behavior. Our data show the functional relevance of targeting this adaptive brake with ISRIB treatment to trigger cytotoxicity during aggressive lethal stages of advanced and castration-resistant PCa, for which at present there is no cure.

## MATERIALS AND METHODS

### Study design

This study was designed to evaluate how two oncogenic lesions, which augment protein synthesis, cooperate in aggressive PCa and prevent

proteotoxic stress to support tumor growth and survival. This objective was addressed by (i) creating mouse models, cell lines, and PDX models that depict the loss of PTEN with or without the overexpression of MYC, (ii) evaluating PCa development downstream of these oncogenes, (iii) observing global changes in newly synthesized proteins, followed by (iv) identifying the adaptive response responsible for our observations. Using a genetic and pharmacological approach in both GEM and PDX models, we inhibited the identified adaptive response to observe the effects on tumor development and growth. TMA analysis was also conducted to investigate the clinical relevance of our findings in association with advanced PCa.

For all experiments, our sample sizes were determined on the basis of experience and published literature, which historically show that these *in vivo* models are penetrant and consistent for tumor development. We used the maximum number of mice available for a given experiment based on the following criteria: the number of GEMMs available in the age range of tumor development and tumor size availability for implantation in PDXs. All mice were randomly assigned to each treatment group for all preclinical trials. Blinded observers visually inspected mice for obvious signs of tumor growth or morbidity including weight loss, hunched posture, or lethargy. MRI tumor recognition, IF imaging, and data collection by flow cytometry were done by researchers blinded to the sample identification after analysis. The number of experimental replicates is specified within each figure legend and elaborated for specific experiments within Supplementary Materials and Methods.

## Statistical analyses

Statistical analyses were performed using Microsoft Excel, GraphPad Prism, or SAS (Statistical Analysis System) 9.4 for Windows, with additional description in Supplementary Materials and Methods. Raw values were depicted when possible or normalized to internal controls from at least three independent experiments, shown as quantitative values expressed as means  $\pm$  SD or SEM, as indicated. Data were analyzed applying unpaired Student's *t* test to compare quantitative data between two independent samples, unless otherwise specified. The Kaplan-Meier method was used for survival analysis. *P* < 0.05 were considered significant and denoted by \**P* < 0.05, \*\**P* < 0.01, or \*\*\**P* < 0.001.

## SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/10/439/eaar2036/DC1

Materials and Methods

Fig. S1. Myc<sup>T9</sup> and PTEN loss cooperate for aggressive PCa development in mice.

Fig. S2. The UPR is activated in murine PCa.

Fig. S3. PERK loss blocks PCa progression and decreases P-eIF2 $\alpha$  expression.

Fig. S4. Loss of P-eIF2 $\alpha$  activity by ISRIB shows no toxicity and does not substantially alter infiltrating immune cells.

Fig. S5. Inhibition of P-eIF2 $\alpha$  activity by ISRIB does not affect human prostatic cell lines' growth.

Fig. S6. PCa tissue from TMA shows specificity of protein expression in benign and tumor cells.

Fig. S7. Treatment with ISRIB or ATF4 siRNA results in increased apoptosis within metastatic tumor.

Fig. S8. A PDX was generated to recapitulate mCRPC.

Table S1. MRI tumor volumes during treatment in GEMMs.

References (49–54)

## REFERENCES AND NOTES

1. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. *Cell* **144**, 646–674 (2011).
2. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and non-oncogene addiction. *Cell* **136**, 823–837 (2009).
3. D. Ruggero, Revisiting the nucleolus: From marker to dynamic integrator of cancer signaling. *Sci. Signal.* **5**, pe38 (2012).

4. D. Ron, P. Walter, Signal integration in the endoplasmic reticulum unfolded protein response. *Nat. Rev. Mol. Cell Biol.* **8**, 519–529 (2007).
5. M. Wang, R. J. Kaufman, The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat. Rev. Cancer* **14**, 581–597 (2014).
6. C. Hetz, E. Chevet, S. A. Oakes, Proteostasis control by the unfolded protein response. *Nat. Cell Biol.* **17**, 829–838 (2015).
7. C. Koumenis, C. Naczki, M. Koritzinsky, S. Rastani, A. Diehl, S. Nahum, A. Koromilas, B. G. Wouters, Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2 $\alpha$ . *Mol. Cell Biol.* **22**, 7405–7416 (2002).
8. D. R. Fels, C. Koumenis, The PERK/eIF2 $\alpha$ /ATF4 module of the UPR in hypoxia resistance and tumor growth. *Cancer Biol. Ther.* **5**, 723–728 (2006).
9. A. C. Hsieh, Y. Liu, M. P. Edlind, N. T. Ingolia, M. R. Janes, A. Sher, E. Y. Shi, C. R. Stumpf, C. Christensen, M. J. Bonham, S. Wang, P. Ren, M. Martin, K. Jessen, M. E. Feldman, J. S. Weissman, K. M. Shokat, C. Rommel, D. Ruggero, The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* **485**, 55–61 (2012).
10. A. C. Hsieh, H. G. Nguyen, L. Wen, M. P. Edlind, P. R. Carroll, W. Kim, D. Ruggero, Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. *Sci. Signal.* **8**, ra116 (2015).
11. C. M. Koh, B. Gurel, S. Sutcliffe, M. J. Aryee, D. Schultz, T. Iwata, M. Uemura, K. I. Zeller, U. Anele, Q. Zheng, J. L. Hicks, W. G. Nelson, C. V. Dang, S. Yegnasubramanian, A. M. De Marzo, Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. *Am. J. Pathol.* **178**, 1824–1834 (2011).
12. A. Kumar, I. Coleman, C. Morrissey, X. Zhang, L. D. True, R. Gulati, R. Etzioni, H. Bolouri, B. Montgomery, T. White, J. M. Lucas, L. G. Brown, R. F. Dumit, N. DeSarkar, C. Higano, E. Y. Yu, R. Coleman, N. Schultz, M. Fang, P. H. Lange, J. Shendure, R. L. Vessella, P. S. Nelson, Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. *Nat. Med.* **22**, 369–378 (2016).
13. H. Beltran, D. Prandi, J. M. Mosquera, M. Benelli, L. Puca, J. Cyrta, C. Marotz, E. Giannopoulou, B. V. S. K. Chakravarthi, S. Varambally, S. A. Tomlins, D. M. Nanus, S. T. Tagawa, E. M. Van Allen, O. Elemento, A. Sboner, L. A. Garraway, M. A. Rubin, F. Demichelis, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat. Med.* **22**, 298–305 (2016).
14. J. T. Cunningham, M. V. Moreno, A. Lodi, S. M. Ronen, D. Ruggero, Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. *Cell* **157**, 1088–1103 (2014).
15. M. Barna, A. Pusic, O. Zollo, M. Costa, N. Kondrashov, E. Rego, P. H. Rao, D. Ruggero, Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. *Nature* **456**, 971–975 (2008).
16. M. Pourdehnad, M. L. Truitt, I. N. Siddiqui, G. S. Ducker, K. M. Shokat, D. Ruggero, Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 11988–11993 (2013).
17. D. Ruggero, The role of Myc-induced protein synthesis in cancer. *Cancer Res.* **69**, 8839–8843 (2009).
18. R. Lesche, M. Groszer, J. Gao, Y. Wang, A. Messing, H. Sun, X. Liu, H. Wu, Cre/*loxP*-mediated inactivation of the murine *Pten* tumor suppressor gene. *Genesis* **32**, 148–149 (2002).
19. Cancer Genome Atlas Research Network, The molecular taxonomy of primary prostate cancer. *Cell* **163**, 1011–1025 (2015).
20. J. Kim, I.-E. A. Eltoum, M. Roh, J. Wang, S. A. Abdulkadir, Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. *PLOS Genet.* **5**, e1000542 (2009).
21. K. Ellwood-Yen, T. G. Graeber, J. Wongvipat, M. L. Iruela-Arispe, J. Zhang, R. Matusik, G. V. Thomas, C. L. Sawyers, Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* **4**, 223–238 (2003).
22. J. Drost, W. R. Karthaus, D. Gao, E. Driehuis, C. L. Sawyers, Y. Chen, H. Clevers, Organoid culture systems for prostate epithelial and cancer tissue. *Nat. Protoc.* **11**, 347–358 (2016).
23. W. R. Karthaus, P. J. Iaquinta, J. Drost, A. Gracanin, R. van Boxtel, J. Wongvipat, C. M. Dowling, D. Gao, H. Begthel, N. Sachs, R. G. J. Vries, E. Cuppen, Y. Chen, C. L. Sawyers, H. C. Clevers, Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell* **159**, 163–175 (2014).
24. J. van Riggelen, A. Yetil, D. W. Felsher, MYC as a regulator of ribosome biogenesis and protein synthesis. *Nat. Rev. Cancer* **10**, 301–309 (2010).
25. M. L. Truitt, D. Ruggero, New frontiers in translational control of the cancer genome. *Nat. Rev. Cancer* **16**, 288–304 (2016).
26. C. Hetz, The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. *Nat. Rev. Mol. Cell Biol.* **13**, 89–102 (2012).
27. C. Sidrauski, J. C. Tsai, M. Kampmann, B. R. Hearn, P. Vedantham, P. Jaishankar, M. Sokabe, A. S. Mendez, B. W. Newton, E. L. Tang, E. Verschuere, J. R. Johnson, N. J. Krogan, C. S. Fraser, J. S. Weissman, A. R. Renfro, P. Walter, Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. *eLife* **4**, e07314 (2015).
28. C. Sidrauski, A. M. McGeachy, N. T. Ingolia, P. Walter, The small molecule ISRIB reverses the effects of eIF2 $\alpha$  phosphorylation on translation and stress granule assembly. *eLife* **4**, e05033 (2015).
29. J. C. Tsai, L. E. Miller-Vedam, A. A. Anand, P. Jaishankar, H. C. Nguyen, A. R. Renfro, A. Frost, P. Walter, Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. *Science* **359**, eaaq0939 (2018).
30. K. Pakos-Zebrucka, I. Koryga, K. Mnich, M. Ljubic, A. Samali, A. M. Gorman, The integrated stress response. *EMBO Rep.* **17**, 1374–1395 (2016).
31. P. Zhang, B. McGrath, S. Li, A. Frank, F. Zambito, J. Reinert, M. Gannon, K. Ma, K. McNaughton, D. R. Cavener, The PERK eukaryotic initiation factor 2 $\alpha$  kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. *Mol. Cell Biol.* **22**, 3864–3874 (2002).
32. A. J. Garcia, M. Ruscetta, T. L. Arenzanac, L. M. Trana, D. Bianci-Frias, E. Syberta, S. J. Priceman, L. Wu, P. S. Nelson, S. T. Smalec, H. Wu, *Pten* null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. *Mol. Cell Biol.* **34**, 2017–2028 (2014).
33. M. R. Cooperberg, D. J. Pasta, E. P. Elkin, M. S. Litwin, D. M. Latini, J. DuChane, P. R. Carroll, The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. *J. Urol.* **173**, 1938–1942 (2005).
34. H. G. Nguyen, C. J. Welty, M. R. Cooperberg, Diagnostic associations of gene expression signatures in prostate cancer tissue. *Curr. Opin. Urol.* **25**, 65–70 (2015).
35. M. R. Cooperberg, J. P. Simko, J. E. Cowan, J. E. Reid, A. Djallilvand, S. Bhatnagar, A. Gutin, J. S. Lanchbury, G. P. Swanson, S. Stone, P. R. Carroll, Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. *J. Clin. Oncol.* **31**, 1428–1434 (2013).
36. D. Lin, A. W. Wyatt, H. Xue, Y. Wang, X. Dong, A. Haegert, R. Wu, S. Brahmabhatt, F. Mo, L. Jong, R. H. Bell, S. Anderson, A. Hurtado-Coll, L. Fazli, M. Sharma, H. Beltran, M. Rubin, M. Cox, P. W. Gout, J. Morris, L. Goldenberg, S. V. Volik, M. E. Gleave, C. C. Collins, Y. Wang, High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. *Cancer Res.* **74**, 1272–1283 (2014).
37. M. S. Cookson, W. T. Lowrance, M. H. Murad, A. S. Kibel; American Urological Association, Castration-resistant prostate cancer: AUA guideline amendment. *J. Urol.* **193**, 491–499 (2015).
38. G. Gundem, P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. C. Tubio, E. Papaemmanuil, D. S. Brewer, H. M. L. Kallio, G. Högnäs, M. Annala, K. Kivinummi, V. Goody, C. Latimer, S. O'Meara, K. J. Dawson, W. Isaacs, M. R. Emmert-Buck, M. Nykter, C. Foster, Z. Kote-Jarai, D. Easton, H. C. Whitaker; ICGC Prostate UK Group, D. E. Neal, C. S. Cooper, R. A. Eeles, T. Visakorpi, P. J. Campbell, U. McDermott, D. C. Wedge, G. S. Bova, The evolutionary history of lethal metastatic prostate cancer. *Nature* **520**, 353–357 (2015).
39. D. Robinson, E. M. Van Allen, Y.-M. Wu, N. Schultz, R. J. Lonigro, J.-M. Mosquera, B. Montgomery, M.-E. Taplin, C. C. Pritchard, G. Attard, H. Beltran, W. M. Abida, R. K. Bradley, J. Vinson, X. Cao, P. Vats, L. P. Kunju, M. Hussain, F. Y. Feng, S. A. Tomlins, K. A. Cooney, D. C. Smith, C. Brennan, J. Siddiqui, R. Mehra, Y. Chen, D. E. Rathkopf, M. J. Morris, S. B. Solomon, J. C. Durack, V. E. Reuter, A. Gopalan, J. Gao, M. Loda, R. T. Lis, M. Bowden, S. P. Balk, G. Gaviola, C. Sougnez, M. Gupta, E. Y. Yu, E. A. Mostaghel, H. H. Cheng, H. Mulcahy, L. D. True, S. R. Plymate, H. Dvinge, R. Ferraldeschi, P. Flohr, S. Miranda, Z. Zafeiriou, N. Tunariu, J. Mateo, R. Perez-Lopez, F. Demichelis, B. D. Robinson, M. A. Schiffman, D. M. Nanus, S. T. Tagawa, A. Sigaras, K. W. Eng, O. Elemento, A. Sboner, E. I. Heath, H. I. Scher, K. J. Pienta, P. Kantoff, J. S. de Bono, M. A. Rubin, P. S. Nelson, L. A. Garraway, C. L. Sawyers, A. M. Chinnaiyan, Integrative clinical genomics of advanced prostate cancer. *Cell* **161**, 1215–1228 (2015).
40. K. Bouchelouche, P. L. Choyke, Advances in prostate-specific membrane antigen PET of prostate cancer. *Curr. Opin. Oncol.* **30**, 189–196 (2018).
41. W. E. Balch, R. I. Morimoto, A. Dillin, J. W. Kelly, Adapting proteostasis for disease intervention. *Science* **319**, 916–919 (2008).
42. E. Karali, S. Bellou, D. Stellas, A. Klinakis, C. Murphy, T. Fotsis, VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. *Mol. Cell* **54**, 559–572 (2014).
43. M. Holcik, N. Sonenberg, Translational control in stress and apoptosis. *Nat. Rev. Mol. Cell Biol.* **6**, 318–327 (2005).
44. N. Robichaud, N. Sonenberg, Translational control and the cancer cell response to stress. *Curr. Opin. Cell Biol.* **45**, 102–109 (2017).
45. M. Bi, C. Naczki, M. Koritzinsky, D. Fels, J. Blais, N. Hu, H. Harding, I. Novoa, M. Varia, J. Raleigh, D. Scheuner, R. J. Kaufman, J. Bell, D. Ron, B. G. Wouters, C. Koumenis, ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. *EMBO J.* **24**, 3470–3481 (2005).
46. P. Walter, D. Ron, The unfolded protein response: From stress pathway to homeostatic regulation. *Science* **334**, 1081–1086 (2011).
47. D. J. Todd, L. J. McHeyzer-Williams, C. Kowal, A.-H. Lee, B. T. Volpe, B. Diamond, M. G. McHeyzer-Williams, L. H. Glimcher, XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. *J. Exp. Med.* **206**, 2151–2159 (2009).

48. A. Sandoel, J. G. Dunn, E. H. Rodriguez, S. Naik, N. C. Gomez, B. Hurwitz, J. LeVorse, B. D. Dill, D. Schramek, H. Molina, J. S. Weissman, E. Fuchs, Translation from unconventional 5' start sites drives tumour initiation. *Nature* **541**, 494–499 (2017).
49. T. Matsuda, C. L. Cepko, Electroporation and RNA interference in the rodent retina in vivo and in vitro. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 16–22 (2004).
50. J.-i Miyazaki, S. Takaki, K. Araki, F. Tashiro, A. Tominaga, K. Takatsu, K.-i Yamamura, Expression vector system based on the chicken  $\beta$ -actin promoter directs efficient production of interleukin-5. *Gene* **79**, 269–277 (1989).
51. E. L. Jackson, N. Willis, K. Mercer, R. T. Bronson, D. Crowley, R. Montoya, T. Jacks, D. A. Tuveson, Analysis of lung tumor initiation and progression using conditional expression of oncogenic *K-ras*. *Genes Dev.* **15**, 3243–3248 (2001).
52. S. Rees, J. Coote, J. Stables, S. Goodson, S. Harris, M. G. Lee, Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. *Biotechniques* **20**, 102–110 (1996).
53. A. Okada, R. Lansford, J. M. Weimann, S. E. Fraser, S. K. McConnell, Imaging cells in the developing nervous system with retrovirus expressing modified green fluorescent protein. *Exp. Neurol.* **156**, 394–406 (1999).
54. D. G. Altman, L. M. McShane, W. Sauerbrei, S. E. Taube, Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. *PLOS Med.* **9**, e1001216 (2012).

**Acknowledgments:** We thank the Mouse Pathology, Preclinical Therapeutics, and Biomedical Imaging Core facilities at University of California, San Francisco (UCSF) for their assistance in our study. We are grateful to J. Simko at UCSF for building the TMA, for providing them for our use, and for assistance in selecting human tumor tissue used in construction of the pPca and mPca PDX models. In addition, we thank M. Barna at Stanford University for the helpful comments provided. **Funding:** H.G.N. is supported by the U.S. Department of Defense (W81XWH-15-1-0460), AUA-SUO-Prostate Cancer Foundation Young Investigator Award (16YOUN14), and AUA Urology Care Foundation Rising Star in Research Award (A130596). C.S.C. is funded by the American Cancer Society (PF-14-212-01-RMC) and the AACR-Bayer Prostate Cancer Research Fellowship (17-40-44-CONN). C.M.F. is funded by the Campini Foundation, The Leukemia and Lymphoma Foundation Career Development Grant, and UCSF Department of Pediatrics K12 (5K12HDO72222-05). A.C.H. was supported by NIH (1K08CA175154-01) and the Burroughs Wellcome Fund Career Award for Medical Scientists. M.J.E. and D.R. are supported by the American Cancer Society (130635-R5G-17-005-01-CCE). C.K. and D.R. are supported by NIH (P01-CA1659970). P.W. is

supported by Calico Life Sciences LLC, the Weill Foundation, and the Howard Hughes Medical Institute. D.R. is a Leukemia and Lymphoma Society Scholar, and this research was funded by NIH grants (R01-CA140456 and R01-CA154916). C.K. and D.R. are supported by NIH (P01-CA165997), and C.K. by NIH (2R01-CA094214). F.T. was supported by NIH (F31CA183569). **Author contributions:** H.G.N., C.S.C., and D.R. provided oversight of the project. H.G.N., P.R.C., and L.X. primarily collected and analyzed data from PDX models and TMA. C.S.C. and Y.K. primarily collected and analyzed data from GEMMs and cell lines used. C.M.F. collected flow data for GEMMs and PDX models. J.E.C. discussed and performed statistical analysis for the TMA supplied under the supervision of P.R.C. The Myc<sup>T9</sup> mouse model was created by J.T.C., and initial GEMM colonies were started by A.C.H. C.T. and M.J.E. assisted for in vivo imaging experiments. C.P.E. and J.C.Y. created and initially characterized the mCRPC PDX model. B.H. aided in preclinical studies for mouse models. F.T. and C.K. provided materials and discussion for studying PERK signaling. P.W. provided materials and discussion for studying P-eIF2 $\alpha$  with ISRIB. C.S.C. and D.R. prepared the manuscript with edits from H.G.N. and Y.K. Additional authors provided edits for their specific contributions. **Competing interests:** P.W. is an inventor on patent 9708247 held by the Regents of the University of California that describes ISRIB and its analogs. Rights to the invention have been licensed by UCSF to Calico. D.R., H.G.N., P.R.C., C.S.C., and L.X. are inventors on patent application pending: Case no, SF2018-128 held the Regents of the University of California that covers development of a novel two protein biomarker analysis for PCa and a clinical version of ISRIB that can be used to target tumor and metastatic progression in patients. All other authors declare that they have no competing interests. **Data and materials availability:** Requests for materials should be addressed to C.S.C. or D.R. and will be provided with the potential of a material transfer agreement. The mCRPC PDXs are available from C.P.E. under a material agreement with UC Davis.

Submitted 12 October 2017  
Resubmitted 24 January 2018  
Accepted 6 April 2018  
Published 2 May 2018  
10.1126/scitranslmed.aar2036

**Citation:** H. G. Nguyen, C. S. Conn, Y. Kye, L. Xue, C. M. Forester, J. E. Cowan, A. C. Hsieh, J. T. Cunningham, C. Truillet, F. Tameire, M. J. Evans, C. P. Evans, J. C. Yang, B. Hann, C. Koumenis, P. Walter, P. R. Carroll, D. Ruggero, Development of a stress response therapy targeting aggressive prostate cancer. *Sci. Transl. Med.* **10**, eaar2036 (2018).

## Development of a stress response therapy targeting aggressive prostate cancer

Hao G. Nguyen, Crystal S. Conn, Yae Kye, Lingru Xue, Craig M. Forester, Janet E. Cowan, Andrew C. Hsieh, John T. Cunningham, Charles Truillet, Feven Tameire, Michael J. Evans, Christopher P. Evans, Joy C. Yang, Byron Hann, Constantinos Koumenis, Peter Walter, Peter R. Carroll and Davide Ruggero

*Sci Transl Med* **10**, eaar2036.  
DOI: 10.1126/scitranslmed.aar2036

### Stressing out prostate cancer

As tumors grow, they undergo a variety of metabolic changes that facilitate their proliferation. Protein synthesis is one of the cellular processes that is altered in cancer cells, because its continued activation helps drive cancer growth. This is not a benign adaptation, however, and unchecked up-regulation of protein synthesis can be toxic to the cells because it promotes cellular stress. As Nguyen *et al.* discovered, prostate cancer cells with a specific combination of mutations can override this stress by activating a protein called eIF2  $\alpha$ , which protects them from excessive protein synthesis. To target this pathway, the authors identified an inhibitor of eIF2  $\alpha$  that blocks this protective mechanism and has therapeutic activity against aggressive and otherwise untreatable prostate cancer.

#### ARTICLE TOOLS

<http://stm.sciencemag.org/content/10/439/eaar2036>

#### SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2018/04/30/10.439.eaar2036.DC1>

#### RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/10/439/eaat3975.full>  
<http://stm.sciencemag.org/content/scitransmed/8/333/333ra47.full>  
<http://stm.sciencemag.org/content/scitransmed/7/312/312re10.full>  
<http://stm.sciencemag.org/content/scitransmed/7/312/312re11.full>  
<http://stm.sciencemag.org/content/scitransmed/11/478/eaau5758.full>  
<http://science.sciencemag.org/content/sci/364/6439/495.full>  
<http://stm.sciencemag.org/content/scitransmed/11/503/eaaw4993.full>  
<http://science.sciencemag.org/content/sci/364/6439/491.full>

#### REFERENCES

This article cites 54 articles, 17 of which you can access for free  
<http://stm.sciencemag.org/content/10/439/eaar2036#BIBL>

#### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

---

*Science Translational Medicine* (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works